P-180A phase 2 study of capecitabine plus oxaliplatin therapy (XELOX) for patients with inoperable/advanced gastric cancer who were resistant/intolerable to fluoropyrimidine, CDDP, taxane, and CPT-11 (OGSG1403). (2nd July 2019) - Kawada, J; Sugimoto, N; Hirokazu, T; Ueda, S; Murakami, K; Nishikawa, K; Kurokawa, Y; Fujitani, K; Kawakami, H; Sakai, D; Shimokawa, T; Satoh, T